Gerardo Fernandez | Eye tracking | Excellence in Innovation

Posted on by sciencefather

Dr. Gerardo Fernandez | Eye tracking | Excellence in Innovation

Gerardo Abel Fernández 🇦🇷, born on October 29, 1976, in Bahía Blanca, Argentina, is a researcher specializing in neuroscience and cognitive science 🧠. He is a professor and adjunct researcher at CONICET, focusing on eye movement-based biomarkers for neurodegenerative diseases 👀. His work integrates philosophy, cognitive psychology, and technology to advance Alzheimer’s diagnosis 🏥.

Profile

Education 🎓

🎓 Gerardo Abel Fernández obtained a degree in Philosophy (2003) from Universidad Nacional del Sur (UNS), Argentina, with a specialization in Logic and Epistemology. He later pursued a PhD in Philosophy (2011) at UNS, with his thesis titled “Dynamic word processing during reading: Mental strategies driving visual exploration”, earning a perfect 10/10 with special mention. His academic journey includes postdoctoral research as a fellow at AGENCIA (ANPCYT) and the DAAD Max Planck Institute in Berlin. His educational background bridges philosophy, neuroscience, and cognitive psychology, forming a solid foundation for his pioneering research in eye movement analysis and Alzheimer’s biomarkers. His expertise in cognitive science and technological innovation has led to the development of diagnostic tools for early neurodegenerative disease detection. 📚🔍🧠

Experience 👨‍🏫

💼 Dr. Gerardo Abel Fernández has extensive experience in neuroscience research and technological innovation. He served as a Professor of Audiovisual Language at UNS (2011–2013) and is currently an Adjunct Researcher at CONICET, focusing on non-endemic degenerative pathologies. He has worked as a Visiting Scholar at Heriot-Watt University and Strathclyde University (UK), contributing to the development of eye-tracking biomarkers for Alzheimer’s disease. Dr. Fernández is also a scientific reviewer for prestigious journals like PlosOne, Journal of Alzheimer’s Disease, and Neuropsychologia. As CTO of Viewmind, he leads biocognitive and functional performance measurement innovations. He has patented cognitive evaluation methods and received grants from institutions like ANPCYT and DAAD. His interdisciplinary expertise spans cognitive neuroscience, machine learning applications in diagnostics, and technological development for neurodegenerative disease assessment. 🏅🔬👁️

Research Interests 🔬

🔬 Dr. Gerardo Abel Fernández specializes in cognitive neuroscience, neurodegenerative disease biomarkers, and eye-tracking technology. His research focuses on early Alzheimer’s detection through oculomotor behavior analysis. He has developed innovative methods to study visual exploration, reading difficulties, and memory impairments in neurodegenerative conditions. His work integrates machine learning and artificial intelligence for cognitive assessment tools. As a Visiting Scholar in the UK, he contributed to developing biomarkers for Alzheimer’s disease. His patented eye-tracking system has clinical applications in detecting mild cognitive impairment and Alzheimer’s disease. He has published extensively in peer-reviewed journals, exploring predictive eye movement models and their correlation with cognitive decline. His cutting-edge research bridges philosophy, neuroscience, and technology, offering non-invasive diagnostic solutions for early-stage neurodegeneration. His ultimate goal is to revolutionize cognitive healthcare through technological innovation. 🧠👁️📊

Awards & Recognitions 🏅

🏆 Dr. Gerardo Abel Fernández has received numerous awards for his contributions to neuroscience, cognitive evaluation, and Alzheimer’s diagnostics. His eye-tracking research for Alzheimer’s detection earned the Dr. José Borda Clinical Psychiatry Prize at the 22nd International Congress of Psychiatry. He won the Novartis Innovation Award for his work on measuring cognitive performance in health and disease. As CTO of Viewmind, his team received international recognition, including the Fit4Start Luxembourg Award for health applications and the Medica Innovation Prize in Düsseldorf. His research and patented cognitive evaluation equipment have been acknowledged by ANMAT (Argentina’s National Administration of Drugs, Foods, and Medical Technology) and INPI (Argentina’s National Patent Office). Dr. Fernández’s groundbreaking innovations in neurocognitive assessments have positioned him as a leading figure in technological advancements for early Alzheimer’s detection. 🏅🧠🔬

Publications 📚

  • Oculomotor behaviors and integrative memory functions in the alzheimer’s clinical syndrome

    Journal of Alzheimer’s Disease
    2021 | Journal article
    DOI: 10.3233/JAD-201189

  • A non-invasive tool for attention-deficit disorder analysis based on gaze tracks.

    ACM International Conference Proceeding Series
    2019 | Conference paper
    DOI: 10.1145/3309772.3309777

  • Microsaccadic behavior when developing a complex dynamical activity

    Journal of Integrative Neuroscience
    2018 | Journal article
    DOI: 10.3233/JIN-170057

    EID:

    2-s2.0-85053731401

Weiping Qin | Neuroscience | Best Researcher Award

Posted on by sciencefather

Prof. Weiping Qin | Neuroscience | Best Researcher Award 🏆

Department of Medicine at The Icahn School of Medicine at Mount Sinai/James J. Peters VAMC, United States.

Dr. Weiping Qin, MD, Ph.D., is a seasoned researcher with extensive experience in molecular biology and spinal cord injury research. Currently serving as a Research Health Science Specialist at the James J. Peters VA Medical Center and a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Dr. Qin has contributed significantly to the fields of neurology, osteoporosis, and molecular endocrinology. With over 15 years of experience in the VA system, his work is recognized through patents, impactful publications, and professional affiliations.

Profile

Scopus

Google Scholar

Education 🎓:

Dr. Qin earned his MD from Fujian Medical University, China, and his PhD in Molecular Biology from Kanazawa University School of Medicine, Japan, under the mentorship of Dr. Seishi Murakami. His postdoctoral training in Psychiatry at Icahn School of Medicine, guided by Dr. Giulio M. Pasinetti, sharpened his focus on neurological mechanisms in chronic illnesses. This solid foundation paved the way for a career dedicated to bridging the gap between molecular research and clinical application. 🎓🔬🧬

Work Experience 💼:

Dr. Qin has held pivotal roles in academia and research. At James J. Peters VA Medical Center, he progressed from Research Health Science Specialist (Grade 13) to Grade 14, contributing to spinal cord injury and neuromuscular health advancements. Concurrently, he served as a faculty member at Mount Sinai, ascending from Assistant to full Professor. Dr. Qin’s global experience includes tenures in China, Japan, and the U.S., where he has driven interdisciplinary collaborations and secured federal research funding. His service also includes membership in VA and NIH review panels, shaping policies and evaluations. 🌍🛠️💡

Awards and Honors 🏆

Dr. Qin’s work has garnered recognition from prominent organizations, including the Military Health System Research Symposium Poster Award and the Sasagawa Medical Research Award. Media outlets like Reuters and The Wall Street Journal have covered his breakthroughs in bone disease treatment. Additionally, his research has been highlighted by the Department of Defense and NIH. These accolades underscore his innovative contributions to molecular and translational medicine. 🏅📰🎖️

Research Interests:

Dr. Qin’s research focuses on the cellular and molecular mechanisms underlying spinal cord injuries and associated neuromuscular disorders. His innovative work aims to develop pharmacological interventions targeting osteoporosis, bone regeneration, and neuroinflammation. Leveraging advanced molecular biology tools, he bridges experimental findings with clinical applications, significantly impacting rehabilitation medicine and patient care. 🔬🦴🧠

📚 Publications 

Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease

Authors: L Ho, W Qin, PN Pompl, Z Xiang, J Wang, Z Zhao, Y Peng, G Cambareri, …

Citations: 775

Year: 2004

Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction

Authors: W Qin, T Yang, L Ho, Z Zhao, J Wang, L Chen, W Zhao, M Thiyagarajan, …

Citations: 759

Year: 2006

PGC-1α expression decreases in the Alzheimer disease brain as a function of dementia

Authors: W Qin, V Haroutunian, P Katsel, CP Cardozo, L Ho, JD Buxbaum, …

Citations: 439

Year: 2009

Caloric restriction attenuates β‐amyloid neuropathology in a mouse model of Alzheimer’s disease

Authors: J Wang, L Ho, W Qin, AB Rocher, I Seror, N Humala, K Maniar, G Dolios, …

Citations: 368

Year: 2005

RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region

Authors: T Yamashita, S Kaneko, Y Shirota, W Qin, T Nomura, K Kobayashi, …

Citations: 334

Year: 1998

Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity

Authors: Y Shirota, H Luo, W Qin, S Kaneko, T Yamashita, K Kobayashi, …

Citations: 325

Year: 2002

Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: A novel mechanism in muscle-bone communication

Authors: Y Qin, Y Peng, W Zhao, J Pan, H Ksiezak-Reding, C Cardozo, Y Wu, …

Citations: 276

Year: 2017

Bone and muscle loss after spinal cord injury: organ interactions

Authors: W Qin, WA Bauman, C Cardozo

Citations: 224

Year: 2010

Calorie restriction attenuates Alzheimer’s disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus)

Authors: W Qin, M Chachich, M Lane, G Roth, M Bryant, R De Cabo, MA Ottinger, …

Citations: 222

Year: 2006

A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

Authors: PN Pompl, L Ho, M Bianchi, T McManus, W Qin, GM Pasinetti

Citations: 178

Year: 2003

Conclusion 

Dr. Weiping Qin exemplifies excellence in research, innovation, and service, making him a strong candidate for the Best Researcher Award. His groundbreaking work in spinal cord injury and molecular biology, coupled with his dedication to the VA system, positions him as a leader in his field. Addressing areas for improvement, such as collaboration and grant acquisition, could further enhance his impact. Nevertheless, his contributions already stand out as transformative and worthy of recognition.